[1] Three-Dimensional Laparoscopic Anatomical Segment 8 Liver Resection with Glissonian Approach

[2] liver imaging reporting and data system (li-rads) version 2014: understanding and application of the diagnostic algorithm

[3] application of local ablative therapies for hepatocellular carcinoma

[4] sarcomatoid hepatocellular carcinoma misdiagnosed as hepatocellular carcinoma:a case report

[5] Regarding "Postresection Period-Specific Hazard of Recurrence as a Framework for Surveillance Strategy in Patients with Hepatocellular Carcinoma: A Multicenter Outcome Study"

[6] Addendum 1:<i>Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma</i>

[7] Prognostic profile of patients with non-viral hepatocellular carcinoma: A comparative study with hepatitis C virus-related hepatocellular carcinoma using data mining analysis.

[8] Targeting hepatocellular carcinoma: Synthesis of new pyrazole-based derivatives, biological evaluation, DNA binding, and molecular modeling studies

[9] Association of CTLA-4 tagging polymorphisms and haplotypes with hepatocellular carcinoma risk: A case-control study.

[10] Ambovex&reg; as a novel immunological modulator drug for the treatment of hepatocellular carcinoma (HCC) in the liver: a Phase II clinical trial

[11] Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

[12] Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma

[13] Intermediate stage hepatocellular carcinoma: a summary review

[14] Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve

[15] Post-translational modifiers of liver kinase B1/serine/threonine kinase 11 in hepatocellular carcinoma

[16] Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives

[17] Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date

[18] Weighing the benefits of hepatocellular carcinoma surveillance against potential harms

[19] Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions

[20] Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria

[21] Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist

[22] Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein

[23] Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)

[24] Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer

[25] Hepatocellular cancer pain: impact and management challenges

[26] Role of Wnt/&beta;-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance

[27] Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

[28] Editorial: charting the future of hepatocellular carcinoma publications

[29] Efficacy of loco-regional treatment for hepatocellular carcinoma prior to living donor liver transplantation: a report from a single center in Egypt

[30] Pretreatment neutrophil&ndash;lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma

[31] Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma

[32] Liver resection versus radiofrequency ablation for hepatitis B virus-related small hepatocellular carcinoma

[33] Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions

[34] Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma

[35] Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review

[36] Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies

[37] Hepatocellular carcinoma: early-stage management challenges

[38] Screening for hepatocellular carcinoma: patient selection and perspectives

[39] Open-label phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L

[40] Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives

[41] A single institution report of 19 hepatocellular carcinoma patients with bile duct tumor thrombus

[42] Needle track seeding after radiofrequency ablation for hepatocellular carcinoma: prevalence, impact, and management challenge

[43] Pediatric hepatocellular carcinoma: challenges and solutions

[44] Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients

[45] Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration

[46] Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date

[47] GPC-3 in hepatocellular carcinoma: current perspectives

[48] Minimally invasive image-guided therapies for hepatocellular carcinoma

[49] Hepatocellular carcinoma: a review

[50] Does alpha-fetoprotein contribute to the mortality and morbidity of human hepatocellular carcinoma? A commentary

[51] Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma

[52] Transarterial radioembolization for hepatocellular carcinoma: a review

[53] Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients

[54] Hepatocellular carcinoma in elderly patients: challenges and solutions

[55] Fibrolamellar hepatocellular carcinoma: current clinical perspectives

[56] Role of endoscopic ultrasound in diagnosis and management of hepatocellular carcinoma

[57] Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma

[58] Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy

[59] Whither&nbsp;&alpha;-FP in the diagnosis of hepatocellular carcinoma?

[60] The androgen receptor as an emerging target in hepatocellular carcinoma

[61] Emerging role of Hpo signaling and YAP in hepatocellular carcinoma

[62] Hapten-enhanced overall survival time in advanced hepatocellular carcinoma by ultro-minimum incision personalized intratumoral chemoimmunotherapy

[63] Hepatocellular carcinoma ablation and possible immunity in the age of nanosecond pulsed electric fields

[64] Early &alpha;-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib

[65] c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma

[66] A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma

[67] Emerging role of Toll-like receptor 4 in hepatocellular carcinoma

[68] Untreated hepatocellular carcinoma in Egypt: outcome and prognostic factors

[69] Welcome to Journal of Hepatocellular Carcinoma

[70] Chemoembolization with drug-eluting microspheres (DEM-TACE) for hepatocellular carcinoma: single-center review of safety and efficacy

[71] Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma

[72] Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments

[73] Potent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft models

[74] Radiological diagnosis of hepatocellular carcinoma

[75] Emerging role of the peroxisome proliferator-activated receptor-gamma in hepatocellular carcinoma

[76] Hepatocellular carcinoma: epidemiology and risk factors

[77] Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series

[78] Clinical utility of imaging for evaluation of hepatocellular carcinoma

[79] Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives

[80] New insights on the role of epigenetic alterations in hepatocellular carcinoma

[81] Potential immunotherapeutic role of interleukin-2 and interleukin-12 combination in patients with hepatocellular carcinoma

[82] Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma

[83] Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma

[84] Micro-ribonucleic acids: potential noninvasive biomarkers for hepatocellular carcinoma

[85] Emerging role of insulin-like growth factor-binding protein 7 in hepatocellular carcinoma

[86] A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of Wnts and the dickkopf family of Wnt inhibitors

[87] Preoperative Neutrophil-to-Lymphocyte Ratio Plus Platelet-to-Lymphocyte Ratio Predicts the Outcomes after Curative Resection for Hepatocellular Carcinoma

[88] Segmental Distribution of Hepatocellular Carcinoma Correlates with Microvascular Invasion in Liver Explants Undergoing Transplantation

[89] Ambovex&reg; as a novel immunological modulator drug for the treatment of hepatocellular carcinoma (HCC) in the liver: a Phase II clinical trial

[90] Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

[91] Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma

[92] Intermediate stage hepatocellular carcinoma: a summary review

[93] Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve

[94] Post-translational modifiers of liver kinase B1/serine/threonine kinase 11 in hepatocellular carcinoma

[95] Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives

[96] Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date

[97] Weighing the benefits of hepatocellular carcinoma surveillance against potential harms

[98] Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions

[99] Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria

[100] Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist

[101] Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein